In her current role, Dr. Scandiuzzi leads in vitro early discovery for safety programs in immunology and immuno-oncology, primarily focusing on large-molecule drug candidates. She is an expert on target validation, translational immunology, and the identification of the efficacy and safety profile of first-in-class therapeutics in immunology and immuno-oncology. Lisa has a MSc in biotechnology from the University of Verona and a PhD in immunology from Paris Descartes University, where she investigated the role of mast cells in glomerulonephritis models. During her post-doctoral research, she worked at the Albert Einstein College of Medicine in New York studying PD-L1 immuno-modulation in ulcerative colitis and cancer and developing novel strategies combining checkpoint inhibition with radiotherapy for lung cancer.
Target Smarter: Translational Tools for Immune Reset in Autoimmune and Allergy Therapeutics
This webinar will explore how CAR-T, B cell-depleting therapies, and mast cell-targeted approaches are reshaping the future of treatment and, more importantly, how it will influence your drug discovery strategies. Whether you’re advancing a new candidate or exploring drug repurposing opportunities, this session delivers insights to help you stay ahead and drive the future of immunology drug discovery. Watch Replay